Observational studyCancer medicine2023
Accelerated epigenetic aging and myopenia in young adult cancer survivors.
Observational study in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06814795 (Feasibility of Medically Tailored Meals for Pediatric Populations at Risk for Disparities in Serious Illness Outcomes Due to Inequities in Social Drivers of Health), which is not on this map. Cited by 16 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Feasibility of Medically Tailored Meals for Pediatric Populations at Risk for Disparities in Serious Illness Outcomes Due to Inequities in Social Drivers of Health (MTM-Kids)
Who cites it
16 citing papers in PubMed, 2 syntheses or guidelines pooled it, 20 citations in OpenAlex.
- Effect of Tumor-Associated Sarcopenia on Swallowing Function in Patients with Cancer: a Systematic Review and Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Sarcopenia interventions targeted at improving muscle health in adults with cancer: a systematic review and meta-analysis.Frontiers in nutrition · 2025Pooled it
- p16GeroScience · 2026Article
- Aging-related deficits accumulation and cancer-related outcomes in testicular and prostate cancer: Cross-sectional and longitudinal findings.Social science & medicine (1982) · 2026Article
- Epigenetic age acceleration measures and chemotoxicity in older adults with early breast cancer.GeroScience · 2026Article
- Review
- Article
- Cultural mismatch and accelerated epigenetic age during the transition to college.Brain, behavior, & immunity - health · 2025Article
- The adverse effects of chemotherapy on bone mass are not prevented by senolytics.Scientific reports · 2025Article
- Cardiometabolic index is negatively associated with the risk of sarcopenia in the middle aged and elderly Chinese: the first longitudinal evidence from CHARLS.BMC public health · 2025Article
- Genetic and epigenetic bases of long-term adverse effects of childhood cancer therapy.Nature reviews. Cancer · 2025Review
- Applicability of epigenetic age models to next-generation methylation arrays.Genome medicine · 2024Article
- A scoping review evaluating physical and cognitive functional outcomes in cancer survivors treated with chemotherapy: charting progress since the 2018 NCI think tank on cancer and aging phenotypes.Journal of cancer survivorship : research and practice · 2024Article
- Current evidence supporting associations of DNA methylation measurements with survivorship burdens in cancer survivors: A scoping review.Cancer medicine · 2024Article
- Assessing Frailty in Gastrointestinal Cancer: Two Diseases in One?Current oncology reports · 2024Review
- Accelerated epigenetic aging and myopenia in young adult cancer survivors.Cancer medicine · 2023Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundYoung adult cancer survivors experience early aging-related morbidities and mortality. Biological aging biomarkers may identify at-risk survivors and increase our understanding of mechanisms underlying this accelerated aging.
methodsUsing an observational study design, we cross-sectionally measured DNA methylation-based epigenetic age in young adult cancer survivors at a tertiary, academic state cancer hospital. Participants were a convenience sample of consecutively enrolled survivors of childhood, adolescent, and young adult cancers treated with either an anthracycline or alkylating agent, and who were at least 3 months post-treatment. Similarly aged healthy comparators were consecutively enrolled. Cancer treatment and treatment intensity were compared to DNA methylation-based epigenetic age and pace of aging.
resultsSixty survivors (58 completing assessments, mean age 20.5 years, range 18-29) and 27 comparators (mean age 20 years, range 17-29) underwent DNA methylation measurement. Survivors were predominantly female (62%) and white (60%) and averaged nearly 6 years post-treatment (range 0.2-25 years). Both epigenetic age (AgeAccelGrim: 1.5 vs. -2.4, p < 0.0001; AgeAccelPheno 2.3 vs. -3.8, p = 0.0013) and pace of aging (DunedinPACE 0.99 vs. 0.83, p < 0.0001) were greater in survivors versus comparators. In case-case adjusted analysis, compared to survivors with normal muscle mass, myopenic survivors had higher AgeAccelGrim (2.2 years, 95% CI 0.02-4.33, p = 0.02), AgeAccelPheno (6.2 years, 2.36-10.09, p < 0.001), and DunedinPACE (0.11, 0.05-0.17, p < 0.001).
conclusionsEpigenetic age is older and pace of aging is faster in young adult cancer survivors compared to noncancer peers, which is evident in the early post-therapy period. Survivors with physiological impairment demonstrate greater epigenetic age advancement. Measures of epigenetic age may identify young adult survivors at higher risk for poor functional and health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.